The DOI matches its Crossref record; 138 of the 138 references it cites were found in a registry or an index.
Nanomedicinal Strategies to Treat Multidrug-Resistant Tumors: Current Progress
Open accessAbstract
Multidrug resistance (MDR) is a major impediment to the success of cancer chemotherapy. P-glycoprotein is an important and the best-known membrane transporter involved in MDR. Several strategies have been used to address MDR, especially P-glycoprotein-mediated drug resistance in tumors. However, clinical success has been limited, largely due to issues regarding lack of efficacy and/or safety. Nanoparticles have shown the ability to target tumors based on their unique physical and biological properties. To date, nanoparticles have been investigated primarily to address P-glycoprotein and the observed improved anticancer efficacy suggests that nanomedicinal strategies provide a new opportunity to overcome MDR. This article focuses on nanotechnology-based formulations and current nanomedicine approaches to address MDR in tumors and discusses the proposed mechanisms of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Diffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664
ABC Transporters: From Microorganisms to Man
Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985
Solid lipid nanoparticles (SLN) for controlled drug delivery â a review of the state of the art
Müller, R. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00087-4 · Cited by 3,759
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
OWENSIII, D., & PEPPAS, N. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.010 · Cited by 3,637
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Nanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
Tumor delivery of macromolecular drugs based on the EPR effect
Torchilin, V. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.011 · Cited by 2,032
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., & Jain, R. K. (1995) · PubMed · Cited by 1,711
Expression of a multidrug-resistance gene in human tumors and tissues.
Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.265 · Cited by 1,544
Tsuruo, T., Iida, H., Tsukagoshi, S., & Sakurai, Y. (1981) · PubMed · Cited by 1,459
Determinants of tumor blood flow: a review.
Jain, R. K. (1988) · PubMed · Cited by 1,379
Batrakova, E. V., & Kabanov, A. V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.04.013 · Cited by 1,278
Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, C. A., & Borst, P. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118214 · Cited by 1,107
Pharmacology of drugs that alter multidrug resistance in cancer.
Ford, J. M., & Hait, W. N. (1990) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00045-6 · Cited by 974
Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics
Padera, T. P., Kadambi, A., di Tomaso, E., Carreira, C. M., Brown, E. B., Boucher, Y., Choi, N. C., Mathisen, D., Wain, J., Mark, E. J., et al. (2002) · Science · doi:10.1126/science.1071420 · Cited by 967
Interstitial-lymphatic mechanisms in the control of extracellular fluid volume
Aukland, K., & Reed, R. K. (1993) · Physiological Reviews · doi:10.1152/physrev.1993.73.1.1 · Cited by 934
Cancer cells compress intratumour vessels
Padera, T. P., Stoll, B. R., Tooredman, J. B., Capen, D., Tomaso, E. D., & Jain, R. K. (2004) · Nature · doi:10.1038/427695a · Cited by 857
The Role of ABC Transporters in Clinical Practice
Leonard, G. D., Fojo, T., & Bates, S. E. (2003) · The Oncologist · doi:10.1634/theoncologist.8-5-411 · Cited by 817
Nanoparticles for drug delivery in cancer treatment
Haley, B., & Frenkel, E. (2008) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.015 · Cited by 791
(1990) · PubMed · Cited by 757
Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization
Fukumura, D., & Jain, R. K. (2007) · Microvascular Research · doi:10.1016/j.mvr.2007.05.003 · Cited by 691
Reduced permeability in CHO cells as a mechanism of resistance to colchicine
Ling, V., & Thompson, L. H. (1974) · Journal of Cellular Physiology · doi:10.1002/jcp.1040830114 · Cited by 686
Mechanisms of Multidrug Resistance in Cancer
Gillet, J.-P., & Gottesman, M. M. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_4 · Cited by 685
Pluronic® block copolymers for overcoming drug resistance in cancer
Kabanov, A. V., Batrakova, E. V., & Alakhov, V. Y. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00047-9 · Cited by 636
When poor solubility becomes an issue: From early stage to proof of concept
Stegemann, S., Leveiller, F., Franchi, D., de Jong, H., & Lindén, H. (2007) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2007.05.110 · Cited by 567
HPMA copolymer–anticancer drug conjugates: design, activity, and mechanism of action
Kopecek, J. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00075-8 · Cited by 562
Hamada, H., & Tsuruo, T. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.20.7785 · Cited by 546
Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers
Rege, B. D., Kao, J. P. Y., & Polli, J. E. (2002) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00055-6 · Cited by 509
Drug Delivery and Transport to Solid Tumors
Jang, S. H., Wientjes, M. G., Lu, D., & Au, J. L.-S. (2003) · Pharmaceutical Research · doi:10.1023/a:1025785505977 · Cited by 483
(2000) · PubMed · Cited by 475
Inhibition of P-Glycoprotein by D-α-Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS)
Dintaman, J. M., & Silverman, J. A. (1999) · Pharmaceutical Research · doi:10.1023/a:1015000503629 · Cited by 426
Pharmacological Strategies for Overcoming Multidrug Resistance
Nobili, S., Landini, I., Giglioni, B., & Mini, E. (2006) · Current Drug Targets · doi:10.2174/138945006777709593 · Cited by 393
La, S. B., Okano, T., & Kataoka, K. (1996) · Journal of Pharmaceutical Sciences · doi:10.1021/js950204r · Cited by 379
Co-Delivery of siRNA and An Anticancer Drug for Treatment of Multidrug-Resistant Cancer
Saad, M., Garbuzenko, O. B., & Minko, T. (2008) · Nanomedicine · doi:10.2217/17435889.3.6.761 · Cited by 367
MDR1 Gene Expression and Treatment Outcome in Acute Myeloid Leukemia
Pirker, R., Wallner, J., Geissler, K., Linkesch, W., Haas, O. A., Bettelheim, P., Hopfner, M., Scherrer, R., Valent, P., Havelec, L., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.10.708 · Cited by 355
New frontiers in nanotechnology for cancer treatment
Alexis, F., Rhee, J.-W., Richie, J. P., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2008) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.017 · Cited by 347
Wong, H. L., Bendayan, R., Rauth, A. M., Xue, H. Y., Babakhanian, K., & Wu, X. Y. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.101154 · Cited by 344
Sahoo, S. K., & Labhasetwar, V. (2005) · Molecular Pharmaceutics · doi:10.1021/mp050032z · Cited by 340
Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody.
Mechetner, E. B., & Roninson, I. B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.13.5824 · Cited by 316
BCL-2: Prevention of Apoptosis as a Mechanism of Drug Resistance
Reed, J. C. (1995) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30104-7 · Cited by 316
Solid lipid nanoparticles as drug delivery systems
Manjunath, K., Reddy, J. S., & Venkateswarlu, V. (2005) · Methods and Findings in Experimental and Clinical Pharmacology · doi:10.1358/mf.2005.27.2.876286 · Cited by 306
Oral insulin delivery by means of solid lipid nanoparticles.
Sarmento, B. F. C. C., Martins, S., Ferreira, D., & Souto, E. B. (2007) · PubMed Central · Cited by 305
Glutathione S-transferases and drug resistance
(1991) · International Journal of Biochemistry · doi:10.1016/0020-711x(91)90023-g · Cited by 305
Patil, Y. B., Swaminathan, S. K., Sadhukha, T., Ma, L., & Panyam, J. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.09.048 · Cited by 304
Alakhov, V. Y., Moskaleva, E. Y., Batrakova, E. V., & Kabanov, A. V. (1996) · Bioconjugate Chemistry · doi:10.1021/bc950093n · Cited by 304
Wong, H. L., Rauth, A. M., Bendayan, R., Manias, J. L., Ramaswamy, M., Liu, Z., Erhan, S. Z., & Wu, X. Y. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0282-x · Cited by 303
Intracellular targeting of polymer-bound drugs for cancer chemotherapy
NORI, A., & KOPECEK, J. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.10.006 · Cited by 303
Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy
Gindy, M. E., & Prud'homme, R. K. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240902932908 · Cited by 298
Role of anthracyclines in the era of targeted therapy
Cortés-Funes, H., & Coronado, C. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0015-3 · Cited by 294
Batrakova, E. V., Li, S., Vinogradov, S. V., Alakhov, V. Y., Miller, D. W., & Kabanov, A. V. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29254-5 · Cited by 292
Dong, X., Mattingly, C. A., Tseng, M. T., Cho, M. J., Liu, Y., Adams, V. R., & Mumper, R. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2747 · Cited by 290
Self-citationMoghimi, S. M., Porter, C. J. H., Muir, I. S., Illum, L., & Davis, S. S. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)91869-e · Cited by 282
Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.
List, A. F., Spier, C., Greer, J., Wolff, S., Hutter, J., Dorr, R., Salmon, S., Futscher, B., Baier, M., & Dalton, W. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.9.1652 · Cited by 274
The Role of the Sinus Wall in the Passage of Erythrocytes Through the Spleen
Chen, L.-T., & Weiss, L. (1973) · Blood · doi:10.1182/blood.v41.4.529.529 · Cited by 269
Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials
Alakhov, V., Klinski, E., Li, S., Pietrzynski, G., Venne, A., Batrakova, E., Bronitch, T., & Kabanov, A. (1999) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/s0927-7765(99)00064-8 · Cited by 266
Batrakova, E. V., Li, S., Alakhov, V. Y., Miller, D. W., & Kabanov, A. V. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.043307 · Cited by 263
Membrane Topology of a Cysteine-less Mutant of Human P-glycoprotein
Loo, T. W., & Clarke, D. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.843 · Cited by 252
Biodegradable, polymeric nanoparticle delivery systems for cancer therapy
Pridgen, E. M., Langer, R., & Farokhzad, O. C. (2007) · Nanomedicine · doi:10.2217/17435889.2.5.669 · Cited by 249
Breast Cancer Resistance Protein Directly Confers SN-38 Resistance of Lung Cancer Cells
Kawabata, S., Oka, M., Shiozawa, K., Tsukamoto, K., Nakatomi, K., Soda, H., Fukuda, M., Ikegami, Y., Sugahara, K., Yamada, Y., et al. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4267 · Cited by 242
Lo, Y.-L. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00163-9 · Cited by 233
Advances in lipid nanodispersions for parenteral drug delivery and targeting
Constantinides, P. P., Chaubal, M. V., & Shorr, R. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.10.013 · Cited by 230
Batrakova, E. V., Li, S., Elmquist, W. F., Miller, D. W., Alakhov, V. Y., & Kabanov, A. V. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2165 · Cited by 229
Arceci, R. (1993) · Blood · doi:10.1182/blood.v81.9.2215.2215 · Cited by 227
Barraud, L., Merle, P., Soma, E., Lefrançois, L., Guerret, S., Chevallier, M., Dubernet, C., Couvreur, P., Trépo, C., & Vitvitski, L. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.12.035 · Cited by 217
Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate
Omelyanenko, V, Kopečková, P., Gentry, C., & Kopeček, J. (1998) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)00235-6 · Cited by 216
Wu, J. H., Lu, Y., Lee, A., Pan, X., Yang, X., Zhao, X. B., & Lee, R. J. (2007) · PubMed · Cited by 216
Recent Progress in Understanding the Mechanism of P-Glycoprotein-mediated Drug Efflux
Loo, T. W., & Clarke, D. M. (2005) · Journal of Membrane Biology · doi:10.1007/s00232-005-0792-1 · Cited by 209
Constantinides, P. P., & Wasan, K. M. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20780 · Cited by 207
Multidrug resistance and the role of P-glycoprotein knockout mice
Schinkel, A. H., Mol, C. A. A. M., Wagenaar, E., van Deemter, L., Smit, J. J. M., & Borst, P. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00130-b · Cited by 199
Minko, T., Kope?kov�, P., & Kope?ek, J. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000401)86:1<108::aid-ijc17>3.0.co;2-8 · Cited by 198
Garcion, E., Lamprecht, A., Heurtault, B., Paillard, A., Aubert-Pouessel, A., Denizot, B., Menei, P., & Benoît, J.-P. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0289 · Cited by 198
Collnot, E.-M., Baldes, C., Wempe, M. F., Hyatt, J., Navarro, L., Edgar, K. J., Schaefer, U. F., & Lehr, C.-M. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.11.005 · Cited by 184
Vascularization of tumors: A review
Shubik, P. (1982) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf00409698 · Cited by 179
Duan, Z., Brakora, K. A., & Seiden, M. V. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.833.3.7 · Cited by 171
An orally delivered small-molecule formulation with antiangiogenic and anticancer activity
Benny, O., Fainaru, O., Adini, A., Cassiola, F., Bazinet, L., Adini, I., Pravda, E., Nahmias, Y., Koirala, S., Corfas, G., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1415 · Cited by 171
de Verdière, A., Dubernet, C., Némati, F., Soma, E., Appel, M., Ferté, J., Bernard, S., Puisieux, F., & Couvreur, P. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.362 · Cited by 168
Lamprecht, A., & Benoit, J.-P. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.02.014 · Cited by 167
Oil-in-water lipid emulsions: implications for parenteral and ocular delivering systems
Tamilvanan, S. (2004) · Progress in Lipid Research · doi:10.1016/j.plipres.2004.09.001 · Cited by 163
Effect of Pluronic P85 on ATPase Activity of Drug Efflux Transporters
Batrakova, E. V., Li, S., Li, Y., Alakhov, V. Y., & Kabanov, A. V. (2004) · Pharmaceutical Research · doi:10.1007/s11095-004-7675-5 · Cited by 158
In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors
Koziara, J. M., Whisman, T. R., Tseng, M. T., & Mumper, R. J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.03.001 · Cited by 158
Self-citationColloidal Carriers for Ophthalmic Drug Delivery
Mainardes, R. M., Urban, M. C. C., Cinto, P. O., Khalil, N. M., Chaud, M. V., Evangelista, R. C., & Gremião, M. P. D. (2005) · Current Drug Targets · doi:10.2174/1389450053765914 · Cited by 155
Tissue Perfusion Inhomogeneity During Early Tumor Growth in Rats 2
Endrich, B., Reinhold, H. S., Joseph F. Gross, P. D., & Intaglietta, M. (1979) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/62.2.387 · Cited by 151
Minko, T., Batrakova, E. V., Li, S., Li, Y., Pakunlu, R. I., Alakhov, V. Y., & Kabanov, A. V. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.03.019 · Cited by 151
Microcirculation of tumors Part I: Anatomy, function, and necrosis
Rubin, P., & Casarett, G. W. (1966) · Clinical Radiology · doi:10.1016/s0009-9260(66)80027-2 · Cited by 147
Alakhova, D. Y., Rapoport, N. Y., Batrakova, E. V., Timoshin, A. A., Li, S., Nicholls, D. G., Alakhov, V. Y., & Kabanov, A. V. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.09.026 · Cited by 145
The effect of verapamil on the pharmacokinetics of adriamycin
Kerr, D. J., Graham, J., Cummings, J., Morrison, J. G., Thompson, G. G., Brodie, M. J., & Kaye, S. B. (1986) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00273394 · Cited by 145
Kast, C., Canfield, V. A., Levenson, R. G., & Gros, P. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.16.9240 · Cited by 143
Bennis, S., Chapey, C., Robert, J., & Couvreur, P. (1994) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80025-5 · Cited by 142
Minko, T., Kopečková, P., & Kopeček, J. (1999) · Pharmaceutical Research · doi:10.1023/a:1018959029186 · Cited by 131
Tsuruo, T., Iida, H., Yamashiro, M., Tsukagoshi, S., & Sakurai, Y. (1982) · Biochemical Pharmacology · doi:10.1016/0006-2952(82)90097-1 · Cited by 131
Shell-crosslinked Pluronic L121 micelles as a drug delivery vehicle
Yang, T.-F., Chen, C., Chen, M., Lai, C.-H., Liang, H., & Sung, H. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.09.035 · Cited by 130
P-glycoprotein and surfactants: Effect on intestinal talinolol absorption
Bogman, K., Aschmann, Y. Z., DEGEN, L., Gérard Hopfgartner, D., Gutmann, H., Alsenz, J., & Drewe, J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.09.001 · Cited by 126
Sensitization of Cells Overexpressing Multidrug-Resistant Proteins by Pluronic P85
Batrakova, E. V., Li, S., Alakhov, V. Y., Elmquist, W. F., Miller, D. W., & Kabanov, A. V. (2003) · Pharmaceutical Research · doi:10.1023/a:1026179132599 · Cited by 125
Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux
Chavanpatil, M. D., Patil, Y. B., & Panyam, J. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.03.045 · Cited by 124
Tumor Physiology and Delivery of Nanopharmaceuticals
Campbell, R. B. (2006) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152006778699077 · Cited by 124
Distribution kinetics of a micelle-forming block copolymer Pluronic P85
Batrakova, E. V., Li, S., Li, Y., Alakhov, V. Y., Elmquist, W. F., & Kabanov, A. V. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.09.002 · Cited by 121
Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells
de Verdière, A. C., Dubernet, C., Némati, F., Poupon, M., Puisieux, F., & Couvreur, P. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686509 · Cited by 119
Surfactant–Polymer Nanoparticles Overcome P-Glycoprotein-Mediated Drug Efflux
Chavanpatil, M. D., Khdair, A., Gérard, B., Bachmeier, C. J., Miller, D. W., Shekhar, M. P. V., & Panyam, J. (2007) · Molecular Pharmaceutics · doi:10.1021/mp070024d · Cited by 117
ABC transporters and inhibitors: new targets, new agents.
Leonard, G. D., Polgár, O., & Bates, S. E. (2002) · PubMed · Cited by 115
Liposome-Mediated Modulation of Multidrug Resistance in Human HL-60 Leukemia Cells
Rahman, A., Husain, S. R., Siddiqui, J. I., Verma, M., Agresti, M., Safa, A. R., & Glazer, R. I. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.24.1909 · Cited by 104
Minko, T., Kopečková, P., & Kopec̆ek, J. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(98)00186-2 · Cited by 97
Carrstensen, H., Müller, R. H., & Müller, B. W. (1992) · Clinical Nutrition · doi:10.1016/0261-5614(92)90006-c · Cited by 95
Colloidal carriers for the enhanced delivery through the skin
Cosco, D., Celia, C., Cilurzo, F., et al. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.7.737 · Cited by 94
Norman, M. E., Williams, P. M., & Illum, L. (1992) · Biomaterials · doi:10.1016/0142-9612(92)90177-p · Cited by 90
Novel PDLLA/PEG copolymer micelles as drug carriers
Piskin, E., Xu, K., Denkbaş, E. B., & Küçükyavuz, Z. (1996) · Journal of Biomaterials Science Polymer Edition · doi:10.1163/156856295x00373 · Cited by 86
Stabilization of Pluronic P-105 Micelles with an Interpenetrating Network of N,N-Diethylacrylamide
Pruitt, J. D., Husseini, G. A., Rapoport, N. Y., & Pitt, W. G. (2000) · Macromolecules · doi:10.1021/ma0008544 · Cited by 81
Icreased drug permeability in Chinese hamster ovary cells in the presence of cyanide
See, Y. P., Carlsen, S. A., Till, J. E., & Ling, V. W. T. (1974) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(74)90148-5 · Cited by 81
Bates, S. E., Kang, M. H., Meadows, B., Bakke, S., Choyke, P. L., Merino, M. J., Goldspiel, B. R., Chico, I. M., Smith, T., Chen, C. C., et al. (2001) · Cancer · Cited by 80
Shionoya, M., Jimbo, T., Kitagawa, M., Soga, T., & Tohgo, A. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01465.x · Cited by 77
Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding
Seelig, A., & Gerebtzoff, G. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.5.733 · Cited by 75
Arao, S., Suwa, H., Mandai, M., et al. (1994) · PubMed · Cited by 74
Wang, J.-C., Goh, B. C., Lü, W.-L., Zhang, Q., Chang, A., Liu, X. Y., Tan, T. M. C., & Lee, H.-S. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.822 · Cited by 70
Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer
Booser, D. J., Esteva, F. J., Rivera, E., Valero, V., Esparza-Guerra, L., Priebe, W., & Hortobágyi, G. N. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0464-0 · Cited by 67
Stewart, A. J., Canitrot, Y., Baracchini, E., Dean, N. M., Deeley, R. G., & Cole, S. P. C. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02220-1 · Cited by 66
LIPOSOMAL DAUNORUBICIN OVERCOMES DRUG RESISTANCE IN HUMAN BREAST, OVARIAN AND LUNG CARCINOMA CELLS
Sadava, D., Coleman, A., & Kane, S. E. (2002) · Journal of Liposome Research · doi:10.1081/lpr-120016196 · Cited by 63
Effect of liposomes on P-glycoprotein function in multidrug resistant cells
Thierry, A. R., Dritschilo, A., & Rahman, A. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)91310-m · Cited by 62
Synthesis and Antitumor Activity of Novel C-7 Paclitaxel Ethers: Discovery of BMS-184476
Altstadt, T. J., Fairchild, C. R., Golik, J., Johnston, K., Kadow, J. F., Lee, F. Y., Long, B. H., Rose, W. C., Vyas, D. M., Wong, H., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0102607 · Cited by 58
Increased accumulation of drugs in multidrug-resistant cells induced by liposomes.
Warren, L., Jardillier, J. C., Malarska, A., & Akeli, M. G. (1992) · PubMed · Cited by 56
Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL).
Marie, J., Bastie, J. N., Coloma, F., Faussat, A., Delmer, A. J., Rio, B., Delmas-Marsalet, B., Leroux, G., Casassus, P., & Baumelou, E. (1993) · PubMed · Cited by 54
Preclinical antitumor activity of two novel taxanes
Rose, W. C., Fairchild, C. A., & Lee, F. Y. F. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800000241 · Cited by 48
The use of GEM models for experimental cancer therapeutics
Gopinathan, A., & Tuveson, D. A. (2008) · Disease Models & Mechanisms · doi:10.1242/dmm.000570 · Cited by 47
Hamberg, L. M., Kristjansen, P. E. G., Hunter, G. J. S., et al. (1994) · PubMed · Cited by 46
Mayer, L. D., & Shabbits, J. A. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1013108524062 · Cited by 39
Yamazaki, T., Sato, Y., Hanai, M., 持丸, 純., Tsujino, I., Sawada, U., & Horie, T. (2000) · Cancer Letters · doi:10.1016/s0304-3835(99)00355-9 · Cited by 38
Pepin, X. J. H., Attali, L., Domrault, C., Gallet, S., Métreau, J. M., Reault, Y., Cardot, P. J. P., Imalalen, M., Dubernet, C., Soma, C. E., et al. (1997) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(97)00362-9 · Cited by 38
Cassinelli, G., Lanzi, C., Supino, R., Pratesi, G., Zuco, V., Laccabue, D., Cuccuru, G., Bombardelli, E., & Zunino, F. (2002) · PubMed · Cited by 36
Drug Delivery in Cancer Using Liposomes
Dass, C. R. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-210-6_9 · Cited by 35
Li, X., Lu, W., Liang, G., Ruan, G. R., Hong, H., Long, C., Zhang, Y., Liu, Y., Wang, J., Zhang, X., et al. (2006) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2006.01643.x · Cited by 32
The Role of Taxanes in the Adjuvant Treatment of Early Stage Breast Cancer
Piccart, M. J. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1024393926965 · Cited by 30
Wang, Y., Eksborg, S., Lewensohn, R., Lindberg, A., & Liliemark, E. (1999) · Anti-Cancer Drugs · doi:10.1097/00001813-199911000-00008 · Cited by 28
Krühn, A., Wang, A., Fruehauf, J. H., & Lage, H. (2009) · Cell Cycle · doi:10.4161/cc.8.20.9845 · Cited by 25
Gatouillat, G., Odot, J., Balasse, E., Nicolau, C. S., Tosi, P., Hickman, D. T., López-Deber, M. P., & Madoulet, C. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.04.001 · Cited by 18
Multi-anticancer drugs encapsulated in the micelle: A novel chemotherapy to cancer
Liu, P., Wang, B., & Li, W. Q. J. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.05.002 · Cited by 18
Cited by
Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells
Kim, M. S., Haney, M. J., Zhao, Y., Mahajan, V., Deygen, I., Klyachko, N. L., Inskoe, E., Piroyan, A., Sokolsky, M., Okolie, O., et al. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.10.012 · Cited by 1,410
Challenges in Development of Nanoparticle-Based Therapeutics
Desai, N. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9339-4 · Cited by 1,173
Wang, F., Wang, Y.-C., Dou, S., Xiong, M.-H., Sun, T.-M., & Wang, J. (2011) · ACS Nano · doi:10.1021/nn200007z · Cited by 813
Nanomedicine therapeutic approaches to overcome cancer drug resistance
Markman, J. L., Rekechenetskiy, A., Holler, E., & Ljubimova, J. Y. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.019 · Cited by 733
“With repeated treatment, tumors often become resistant not only to the specific chemotherapeutic agent being employed, but cross-resistant to both similar and structurally unrelated classes of cytotoxic drugs [16-18].”
BackgroundHe, Q., & Shi, J. (2014) · Advanced Materials · doi:10.1002/adma.201303123 · Cited by 482
Metadata
- Authors
- Dong, X., & Mumper, R. J.
- Venue
- Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2010-06
- Volume
- 5
- Issue
- 4
- Pages
- 597-615
- ISSN
- 1743-5889 (ISSN-L)
- 1748-6963
- OpenAlex
- W2119203526
- Cited by
- 317
- References
- 138
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.